Comparative Pharmacology
Head-to-head clinical analysis: INLYTA versus SCEMBLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INLYTA versus SCEMBLIX.
INLYTA vs SCEMBLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
200 mg orally once daily with a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor, Antineoplastic